COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.

Publication date: Mar 22, 2024

GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection. Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity. Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1-2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects. We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.

Concepts Keywords
Astrazeneca COVID-19
Canada Reactogenicity
Tiredness SARS-CoV-2
Vaccines Vaccine safety


Type Source Name
disease VO COVID-19 vaccine
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease VO Canada
disease VO vaccination
disease VO vaccine

Original Article

(Visited 1 times, 1 visits today)